摘要
目的 利用快速卫生技术评估(rHTA)方法评估血塞通注射液治疗中风的有效性、安全性和经济性,为临床合理用药提供参考。方法 检索万方医学网、中国生物医学文献数据库、中国知网、PubMed、Cochrane Library、Embase等数据库以及国际卫生技术评估网络、国际卫生技术评估协会等网站,对血塞通注射液治疗中风的HTA报告、Meta分析/系统评价、药物经济学研究等资料进行汇总分析。结果 共纳入29篇文献,其中14篇为Meta分析/系统评价、15篇为药物经济学研究,未检索到HTA报告。Meta分析/系统评价结果显示,血塞通注射液治疗中风在提高总有效率、改善临床症状及相关量表评分等方面与空白对照组及部分药物对照组相比具有一定优势。安全性研究显示,血塞通注射液不良反应以过敏样反应为主。药物经济学评价的结果差异较大,可能与各项研究之间时间跨度较长、部分药物价格有所调整相关。结论 血塞通注射液治疗中风有助于提高临床疗效,改善评价指标,但存在部分严重不良反应,且与部分化学药相比经济性并不占优势。
OBJECTIVE To evaluate the efficacy, safety and economical efficiency of Xuesaitong injection in the treatment of stroke by rapid health technology assessment,so as to provide evidence for clinical rational drug use. METHODS Retrieved from Wanfang database, CBM, CNKI,PubMed,Cochrane Library,Embase, INAHTA and HTAI databases or organization websites, health technology assessment(HTA) reports, meta-analysis/systematic reviews and pharmacoeconomic studies related to Xuesaitong injection in the treatment of stroke were summarized and analyzed. RESULTS A total of 29 pieces of literature were included.Among them, 14 studies were conducted on meta-analysis/systematic reviews,15 studies were conducted on pharmacoeconomics, HTA was not obtained. The results of meta-analysis/systematic reviews showed that Xuesaitong injection had certain advantages for stroke in improving the total effective rate, clinical symptoms and related scale scores compared with blank control group and some drug control groups. Safety studies had shown that the adverse reactions of Xuesaitong injection were mainly allergic-like reactions.The results of pharmacoeconomic evaluation are quite different, which may also be related to the long time span among various studies and the adjustment of some drug prices. CONCLUSIONS Xuesaitong injection in the treatment of stroke is helpful to improve the clinical efficacy and evaluation indexes, but there are some serious adverse reactions, and it is not economically superior to some chemical drugs.
作者
张碧华
邵晖
叶爱军
杨莉萍
ZHANG Bihua;SHAO Hui;YE Aijun;YANG Liping(Dept.of Pharmacy,Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine,Chinese Academy of Medical Sciences/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China;Dept of Audit,Beijing Xuanwu Hospital of Traditional Chinese Medicine,Beijing 100050,China)
出处
《中国药房》
CAS
北大核心
2023年第1期97-101,共5页
China Pharmacy
基金
北京市中医药科技发展资金资助项目(No.JJ-2020-32)。
关键词
血塞通注射液
中风
药物经济学
快速卫生技术评估
Xuesaitong injection
stroke
pharmacoeconomics
rapid health technology assessment